Literature DB >> 14529313

Viral and non-viral vectors in gene therapy: technology development and clinical trials.

Kenneth Lundstrom1, Teni Boulikas.   

Abstract

Gene therapy as part of modern molecular medicine holds great promise for the treatment of both acute and chronic diseases and has the potential to bring a revolutionary era to cancer treatment. Gene therapy has been named the medicine of the future. For the past 10 years various viral and non-viral vectors have been engineered for improved gene and drug delivery. Although various diseases have been targeted, cancer therapy has been addressed to a large extent because of the straight forward approach. Delivery of toxic or immunostimulatory genes by viral and non-viral vectors has been investigated and encouraging results have been obtained in animal models. A large number of clinical trials have been conducted with some highly promising outcome. We propose that combinations of viruses with liposomes or polymers will solve the problem of systemic viral delivery and tumor targeting, bringing a revolution in molecular medicine and in applications of gene therapy in humans.

Entities:  

Mesh:

Year:  2003        PMID: 14529313     DOI: 10.1177/153303460300200513

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  22 in total

1.  The Gordon Wilson lecture: using genetic medicine to regenerate diseased organs and protect against the hostile environment.

Authors:  Timothy P O'Connor; Ronald G Crystal
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

Review 2.  Gene therapy: regulations, ethics and its practicalities in liver disease.

Authors:  Xi Jin; Yi-Da Yang; You-Ming Li
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

Review 3.  Non viral vectors in gene therapy- an overview.

Authors:  Murali Ramamoorth; Aparna Narvekar
Journal:  J Clin Diagn Res       Date:  2015-01-01

Review 4.  Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.

Authors:  S Guan; J Rosenecker
Journal:  Gene Ther       Date:  2017-01-17       Impact factor: 5.250

5.  Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.

Authors:  Piotr G Rychahou; Lindsey N Jackson; Scott R Silva; Srinivasan Rajaraman; B Mark Evers
Journal:  Ann Surg       Date:  2006-06       Impact factor: 12.969

Review 6.  Non-viral based miR delivery and recent developments.

Authors:  Annalise Elizabeth Labatut; George Mattheolabakis
Journal:  Eur J Pharm Biopharm       Date:  2018-04-19       Impact factor: 5.571

Review 7.  Nanomedicines for Endometriosis: Lessons Learned from Cancer Research.

Authors:  Abraham S Moses; Ananiya A Demessie; Olena Taratula; Tetiana Korzun; Ov D Slayden; Oleh Taratula
Journal:  Small       Date:  2021-01-25       Impact factor: 13.281

8.  Establishment of mass spectrometric fingerprints of novel synthetic cholesteryl neoglycolipids: the presence of a unique C-glycoside species during electrospray ionization and during collision-induced dissociation tandem mass spectrometry.

Authors:  Anas El-Aneed; Joseph Banoub; Mariano Koen-Alonso; Paul Boullanger; Dominique Lafont
Journal:  J Am Soc Mass Spectrom       Date:  2006-11-07       Impact factor: 3.109

Review 9.  The potential of micelleplexes as a therapeutic strategy for osteosarcoma disease.

Authors:  Catarina Melim; Ivana Jarak; Francisco Veiga; Ana Figueiras
Journal:  3 Biotech       Date:  2020-03-02       Impact factor: 2.406

Review 10.  Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy.

Authors:  Simeon K Adesina; Emmanuel O Akala
Journal:  Mol Pharm       Date:  2015-11-09       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.